endocrine receptor positive breast cancer
Showing 1 - 25 of >10,000
HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine
Recruiting
- HR Positive/HER2 Low Expression Metastatic Breast Cancer
- Disitamab vedotin
- Endocrine therapy
-
Guangzhou, Guangdong, China
- +2 more
Jun 19, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
Breast Cancer Trial in New York (core needle biopsy, blood draw)
Recruiting
- Breast Cancer
- core needle biopsy
- blood draw
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Nov 9, 2023
Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)
Not yet recruiting
- Breast Neoplasms
- Disitamab Vedotin
- Toripalimab
-
Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
- +2 more
Oct 23, 2023
Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
-
Tuebingen, GermanyDepartment of Women's Health
Jun 1, 2023
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,
Not yet recruiting
- Locoregional Recurrence
- +2 more
- Ribociclib
- +4 more
- (no location specified)
Jul 18, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in Duarte
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +3 more
- Abemaciclib
- Questionnaire Administration
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 1, 2022
Female Breast Cancer Trial in Sohag (Hormonal Antineoplastics, Chemotherapy drug)
Not yet recruiting
- Female Breast Cancer
- Hormonal Antineoplastics
- Chemotherapy drug
-
Sohag, Egyptamal Ali
Feb 23, 2023
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab
Recruiting
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
- Sacituzumab Govitecan-hziy
- +3 more
-
Marietta, Georgia
- +1 more
Apr 21, 2023
Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer Trial in Seoul (Ovarian function suppression with
Not yet recruiting
- Breast Cancer
- +4 more
- Ovarian function suppression with endocrine treatments
-
Seoul, Korea, Korea, Republic ofGangnam Severance Hospital
Dec 18, 2022
Breast Cancer Trial in Beijing, Guangzhou (TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole,
Not yet recruiting
- Breast Cancer
- TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
- Placebo capsules, Letrozole, Anastrozole, Tamoxifen
-
Beijing, Beijing, China
- +1 more
Mar 10, 2023
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer Trial in
Recruiting
- Hormone Receptor Positive Breast Carcinoma
- +2 more
- Alpelisib
- +2 more
-
Chicago, Illinois
- +2 more
Jul 1, 2022
Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)
Recruiting
- Locally Advanced Breast Cancer
- Hormone Receptor Positiveļ¼HER2-negative Breast Cancer
-
Jinan, Shandong, ChinaBreast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023
Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer
Active, not recruiting
- Hormone-receptor-positive Breast Cancer
- +2 more
- No drug
-
Cambridge, MassachusettsConcertAI database
Sep 8, 2023
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)
Not yet recruiting
- Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
- Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
-
Singapore, SingaporeNational Cancer Centre Singapore
Oct 13, 2022
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Blood and Tumor Samples From Advanced or Metastatic Estrogen
Active, not recruiting
- Advanced Breast Carcinoma
- +8 more
- Biopsy
- +2 more
-
Scottsdale, Arizona
- +2 more
Jan 3, 2023
Metastatic Breast Cancer Trial in Dallas (DB-1303, Capecitabine, Paclitaxel)
Not yet recruiting
- Metastatic Breast Cancer
- DB-1303
- +3 more
-
Dallas, TexasTexas Oncology - Baylor Charles A. Sammons Cancer Center
Aug 25, 2023
Estrogen Receptor Positive Breast Cancer, Breast Tumor, Metastatic Breast Cancer Trial in Philadelphia ([18F]FES)
Active, not recruiting
- Estrogen Receptor Positive Breast Cancer
- +2 more
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Hospital
Jul 5, 2022
